350 related articles for article (PubMed ID: 22921412)
21. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
22. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
[TBL] [Abstract][Full Text] [Related]
23. Pitfall of hepatitis B surface antigen testing in a kidney transplant recipient presenting hepatitis B reactivation.
Romanet P; Vacher-Coponat H; Moal V; Botta-Fridlund D; Motte A; Colson P
Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):671-4. PubMed ID: 21703961
[TBL] [Abstract][Full Text] [Related]
24. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.
Abdelmalek MF; Pasha TM; Zein NN; Persing DH; Wiesner RH; Douglas DD
Liver Transpl; 2003 Dec; 9(12):1253-7. PubMed ID: 14625824
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus infection in allogeneic bone marrow transplantation.
Ustün C; Koç H; Karayalcin S; Akyol G; Gürman G; Ilhan O; Akan H; Ozcan M; Arslan O; Konuk N; Uysal A; Beksaç M
Bone Marrow Transplant; 1997 Aug; 20(4):289-96. PubMed ID: 9285543
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers.
Chen GD; Gu JL; Qiu J; Chen LZ
Transpl Infect Dis; 2013 Jun; 15(3):300-5. PubMed ID: 23473005
[TBL] [Abstract][Full Text] [Related]
28. Outcome of hepatitis B and C virus infection on graft function after renal transplantation.
Behzad-Behbahani A; Mojiri A; Tabei SZ; Farhadi-Andarabi A; Pouransari R; Yaghobi R; Rahsaz M; Banihashemi M; Malek-Hosseini SA; Javid A; Bahador A; Reisjalali A; Behzadi S; Salehipour M; Salahl A; Davari R; Janghorban P; Torb A; Salah AR
Transplant Proc; 2005 Sep; 37(7):3045-7. PubMed ID: 16213299
[TBL] [Abstract][Full Text] [Related]
29. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
Gupta S; Singh S
BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?
Ferraro D; Pizzillo P; Di Marco V; Vultaggio A; Iannitto E; Venezia G; Craxì A; Di Stefano R
Liver Int; 2009 Sep; 29(8):1171-7. PubMed ID: 19602139
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
[TBL] [Abstract][Full Text] [Related]
32. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
Viganò M; Vener C; Lampertico P; Annaloro C; Pichoud C; Zoulim F; Facchetti F; Poli F; Scalamogna M; Deliliers GL; Colombo M
Bone Marrow Transplant; 2011 Jan; 46(1):125-31. PubMed ID: 20383209
[TBL] [Abstract][Full Text] [Related]
33. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
36. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation.
Gärtner BC; Jung W; Welsch C; Fischinger J; Schubert J; Zeuzem S; Mueller-Lantzsch N; Wend UC; Gerlich WH
J Clin Virol; 2007 Feb; 38(2):146-8. PubMed ID: 17182277
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.
Awerkiew S; Däumer M; Reiser M; Wend UC; Pfister H; Kaiser R; Willems WR; Gerlich WH
J Clin Virol; 2007 Jan; 38(1):83-6. PubMed ID: 17134939
[TBL] [Abstract][Full Text] [Related]
38. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
Rodríguez-Torres M; Gonzalez-Garcia J; Bräu N; Solá R; Moreno S; Rockstroh J; Smaill F; Mendes-Correa MC; DePamphilis J; Torriani FJ;
J Med Virol; 2007 Jun; 79(6):694-700. PubMed ID: 17457912
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
40. Presence of Hepatitis B Surface Antibody in Addition to Hepatitis B Core Antibody Confers Protection Against Hepatitis B Virus Infection in Hepatitis B Surface Antigen-negative Patients Undergoing Kidney Transplantation.
Jeon JW; Kim SM; Cho H; Baek CH; Kim H; Shin S; Kim YH; Han DJ; Kim SB
Transplantation; 2018 Oct; 102(10):1717-1723. PubMed ID: 29621059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
